Browse diseases

…Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common…

…Objective Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related deaths in t…

…tal metastases include breast carcinoma, malignant melanoma and prostate carcinoma. Hepatocellular carcinoma (HCC) is an uncommon source of all re…

…herapy to transplantation/resection or palliative treatment for hepatocellular carcinoma (HCC). Multiple prediction models have been developed for progn…

…t, we discuss how etiological heterogeneity (viral vs non-viral HCC) may confound regimen-specific immune signatures. Second, we hi…

…) is a standard first-line therapy for intermediate-to-advanced hepatocellular carcinoma (HCC), aiming to reduce tumor burden and prolong survival. Howe…

…ever, no statistically significant association was observed for pancreatic cancer (HR 1.26; 95% CI: 0.87-1.82; p=0.224). Additionally, the elevat…

…lance guidance highlighting that early treatment of varices and hepatocellular carcinoma (HCC) reduces morbidity and mortality. We hypothesised that the…

…NHS England published minimum standards for the surveillance of Hepatocellular carcinoma (HCC). It encouraged pathway navigators into the service to imp…

…t regimens targeting immune checkpoint inhibitors, including in hepatocellular carcinoma (HCC).1 Genetic and epigenetic intratumour heterogeneity, as we…

…us targeted therapy with or without immunotherapy. MVI-positive HCC derives added benefit from adjuvant tyrosine kinase inhibitors …

…50%–57.10%), hepatocellular carcinoma (HCC) (13.10%–17.10%) and non-alcoholic fatty liver disease (3.15%–5.08%) increased over time. Similar trends were observed…